# China NMPA Product Recall - Bacterial lysate (trade name: Lanjunjing)

Source: https://www.keypedia.com/records/china_product_recall/italian-pharmaceutical-company-besti/ca05cf2d-2cc7-45d1-990e-ed5b1dc65b08
Source feed: China

> China NMPA product recall for Bacterial lysate (trade name: Lanjunjing) by Italian pharmaceutical company Besti published July 17, 2017. Recall level: . Guangdong Ben Cao Pharmaceutical Group Co., Ltd., the authorized distributor for Besti Pharmaceutica

---

## Details

- Record Type: CHINA_PRODUCT_RECALL
- Title: Guangdong Ben Cao Pharmaceutical Group Co., Ltd. has voluntarily recalled the bacterial lysate (trade name: Lan Jun Jing) from the Italian pharmaceutical company Besti, which it distributes.
- Company Name: Italian pharmaceutical company Besti
- Publication Date: 2017-07-17
- Product Name: Bacterial lysate (trade name: Lanjunjing)
- Recall Reason: Imports have been suspended due to non-compliance with my country's Good Manufacturing Practices for Pharmaceuticals.
- Discovering Company: Guangdong Herbal Medicine Group Co., Ltd.
- Manufacturing Company: Italian pharmaceutical company Besti
- Summary: Guangdong Ben Cao Pharmaceutical Group Co., Ltd., the authorized distributor for Besti Pharmaceuticals of Italy, has conducted a voluntary recall of their Bacterial Lysate (trade name: Lan Jun Jing). This significant action stems from a National Medical Products Administration (NMPA) announcement dated January 18, 2016, which determined that the imported product failed to meet China's Good Manufacturing Practices for Pharmaceuticals (GMP). As a direct consequence of this non-compliance, the NMPA had previously halted the importation of this particular drug. In response to the regulatory findings, Guangdong Ben Cao Pharmaceutical Group Co., Ltd. proactively initiated the recall of all affected batches of Bacterial Lysate that had successfully cleared customs and were distributed within the country. The comprehensive recall encompasses numerous batches, amounting to a total of 598,764 bottles of the 18ml product. This measure is imperative to uphold the integrity of pharmaceutical standards and protect public health. The NMPA's decisive regulatory action highlights the critical importance of strict adherence to manufacturing quality requirements for all medications circulating in the Chinese market, regardless of their origin.

Company: https://www.keypedia.com/companies/italian-pharmaceutical-company-besti/5ed32917-3da0-4f9e-b861-84faa4a074f0